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Abstract The aim of the study was to compare efficacy
and safety of first-line palliative chemotherapy with (EOX)
epirubicin/oxaliplatin/capecitabine and (mDCF) doc-
etaxel/cisplatin/5FU/leucovorin regimens for untreated
advanced HER2-negative gastric or gastroesophageal
junction adenocarcinoma. Fifty-six patients were randomly
assigned to mDCF (docetaxel 40 mg/m2 day 1, leucovorin
400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1, 5FU
1000 mg/m2/d days 1 and 2, cisplatin 40 mg/m2 day 3) or
EOX (epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2
day 1, capecitabine 1250 mg/m2/d days 1–21). The primary
endpoint was overall survival. The median overall survival
was 9.5 months with EOX and 11.9 months with mDCF
(p = 0.135), while median progression-free survival was
6.4 and 6.8 months, respectively (p = 0.440). Two-year
survival rate was 22.2 % with mDCF compared to 5.2 %
with EOX. Patients in the EOX arm had more frequent
reductions in chemotherapy doses (34.5 vs. 3.7 %;
p = 0.010) and delays in subsequent chemotherapy cycles
(82.8 vs. 63.0 %; p = 0.171). There was no statistically
significant difference in the rates of grade 3–4 adverse
events (EOX 79.3 vs. mDCF 61.5 %; p = 0.234). As
compared with the mDCF, the EOX regimen was associ-
ated with more frequent nausea (34.5 vs. 15.4 %), throm-
boembolic events (13.8 vs. 7.7 %), abdominal pain (13.8
vs. 7.7 %) and grades 3–4 neutropenia (72.4 vs. 50.0 %),
but lower incidences of anemia (44.8 vs. 61.5 %),
mucositis (6.9 vs. 15.4 %) and peripheral neuropathy (6.9
vs. 15.4 %). In conclusion, the mDCF regimen was asso-
ciated with a statistically nonsignificant 2.4-month longer
median overall survival without an increase in toxicity.
This trial is registered at ClinicalTrials.gov, number
NCT02445209.
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Introduction
Worldwide, gastric cancer is the fourth most common
malignancy and the second leading cause of cancer death
[1]. Around 2/3 of cases are diagnosed in locally advanced
or metastatic stage, where palliative chemotherapy is the
main treatment option. The prognosis for patients with
advanced gastric cancer receiving no treatment is poor,
with a median overall survival of 3–5 months [2–4]. A few
randomized trials and meta-analysis showed an improve-
ment in weighted average survival of about 6 months in
patients treated with palliative chemotherapy [2–5], their
prognosis, however, is still poor with 5-year survival rates
of 5–20 % and median overall survival\12 months. There
is no single, global standard regimen for the first-line
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treatment of advanced disease. The most common
chemotherapy combinations in the first-line setting consist
of two or three drugs and are cisplatin and fluoropyrimidine
based. The meta-analysis showed an improvement in
weighted average survival of approximately 2 months with
addition of antracycline to cisplatin and 5FU regimen [5],
and ECF combination (epirubicin/cisplatin/5FU) became a
standard in many countries for treating this disease. In a
randomized phase 3 trial, oxaliplatin and capecitabine were
non-inferior to cisplatin and 5FU, respectively, and the
EOX regimen (epirubicin/oxaliplatin/capecitabine) was
associated with the longest overall survival of 11.2 months
[6]. The addition of docetaxel to cisplatin and 5FU (DCF
regimen) improved survival of patients compared to cis-
platin and 5FU alone in a phase 3 trial [7]; however, this
three-drug combination was associated with a significant
toxicity. The modified DCF (mDCF) regimen has recently
been shown to have at least equal efficacy and lower tox-
icity compared to standard DCF chemotherapy in a phase 2
trial [8]. The EOX regimen is usually administered in the
chemotherapy day unit with epirubicin and oxaliplatin
given intravenously and capecitabine administered in the
ambulatory setting, and is repeated every 3 weeks. Thus,
the regimen seems appropriate for patients who wish to
maintain high life activity without being hospitalized. On
the other hand, the mDCF regimen, repeated every
2 weeks, usually requires at least a 3-day hospitalization
due to continuous intravenous administration of 5FU and
hydration for cisplatin. The aim of the study was to com-
pare the efficacy and toxicity of the first-line palliative
three-drug chemotherapy with EOX and mDCF regimens,
respectively, in patients with (HER2) human epidermal
growth factor receptor 2 negative, locally advanced inop-
erable or metastatic gastric or gastroesophageal junction
adenocarcinoma.
Patients and methods
Patient characteristics
This was a randomized, single-centre phase 3 study.
Patients older than 18 years of age were eligible for
inclusion if they had histologically confirmed inoperable
locally advanced, recurrent or metastatic adenocarcinoma
of the stomach or gastro-oesophageal junction; (ECOG)
Eastern Cooperative Oncology Group performance status
0–2; adequate renal, hepatic and hematologic function; and
measurable or non-measurable disease according to the
Response Evaluation Criteria in Solid Tumors (RECIST).
Patients with intraoperatively confirmed intraperitoneal
metastases but without detectable disease in radiological
studies were also eligible. Major exclusion criteria
included: HER2-positive tumors, previous chemotherapy
for metastatic or locally advanced disease, congestive heart
failure, significant dysphagia that would preclude oral
administration of capecitabine, concurrent cancer and evi-
dence of brain metastases. Tumors were tested for HER2
status with immunohistochemistry (IHC) and fluorescence
in situ hybridisation (FISH). Patients with IHC3 ? or
IHC2 ? and FISH-positive results were excluded from the
study. The protocol of the study was approved by a uni-
versity ethics committee. Patients provided written
informed consent, and the study was carried out in accor-
dance with Good Clinical Practice guidelines and the
provisions of the Declaration of Helsinki. All the data were
collected and managed by the physicians of the Department
of Oncology at the University Hospital in Krakow. This
was an academic study with no external sponsors.
Treatment
With the use of random permuted blocks, patients who
fulfilled all eligibility criteria were assigned (1:1) to either
EOX or mDCF chemotherapy. The EOX regimen was
given every 3 weeks, initially for a maximum of eight
cycles (24 weeks of treatment). It consisted of epirubicin
50 mg/m2 (intravenous bolus), followed by oxaliplatin
130 mg/m2 (2-h intravenous infusion); capecitabine was
administered orally, twice daily at the dose of 625 mg/m2
for 21 days. The mDCF regimen was administered every
2 weeks, initially for a maximum of 12 cycles (24 weeks of
treatment), docetaxel 40 mg/m2 (intravenous infusion over
60 min) on day 1, followed by leucovorin 400 mg/m2
(intravenous infusion over 120 min) on day 1, followed by
5-fluorouracil 400 mg/m2 (intravenous bolus) on day 1, and
then 5-fluorouracil 1000 mg/m2/day continuous intra-
venous infusion on day 1 and day 2, followed by cisplatin
40 mg/m2 (intravenous infusion over 60 min) on day 3. All
patients received appropriate hydration and premedication
which were at the discretion of the treating physician.
Chemotherapy dose adjustments and treatment delays were
allowed and were at the discretion of the treating physician.
Treatment continued until disease progression, unaccept-
able toxicity, death or consent withdrawal. Patients who
experienced a long-term response to the initial eight cycles
of EOX or 12 cycles of mDCF chemotherapy had the
possibility of being rechallenged with the same regimen
(the decision was at the discretion of a treating physician).
After progression, eligible patients were treated with the
second-line irinotecan monotherapy.
Evaluation and outcomes
Before random assignment, a complete evaluation was
carried out; it included full medical history, physical
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examination, complete blood count, serum biochemical
analysis and electrocardiography. Echocardiography was
obligatory in patients with signs or history of heart failure or
history of coronary artery disease. Baseline tumor assess-
ments, including computed tomography of the abdomen
(and pelvis in female patients) and chest X-ray, were per-
formed within 28 days before treatment initiation. If the
chest X-ray was suspicious for metastases or the patient
presented symptoms of metastases in the chest, a computed
tomography of the chest was performed. Tumor assessments
were initially planned to be repeated every 8–9 weeks dur-
ing the active treatment phase of the study. However, taking
into account it was not a sponsored trial and access to CT
scans was limited, we adopted our routine clinical strategy to
perform CT scans every 8–12 weeks. Disease progression
could also be evaluated based on clinical symptoms and
urgent CT was requested whenever needed. After the active
treatment phase of the study, subsequent CT scans were
performed every 12 weeks (±2 weeks) or whenever needed
depending on the symptoms. However, progression-free
survival was not a primary endpoint of the study. Toxicities
were graded according to the Common Toxicity Criteria
Adverse Events (CTCAE) version 4.0.
The primary endpoint was overall survival defined as
time from randomization until death from any cause.
Secondary endpoints were progression-free survival and
safety. All randomized patients received study medication
at least once and were included in the analysis. Patients
without an event (death) were censored at the date that they
were last known to be alive.
Statistical analysis
Continuous variables were presented as means and stan-
dard deviations. Categorical variables were presented as
counts and percentages. For continuous variables, statisti-
cal significance of differences between two independent
groups was assessed using t test. For two categorical
variables, the Fisher exact test was used. The Kaplan–
Meier method was used to estimate the survival distribu-
tions. Survival distributions were compared using the log-
rank test. A p value\0.05 was considered an indication of
a statistically significant result. No adjustment for multiple
comparisons was made. All statistical analyses were per-
formed using R 3.0
Results
Patients
Between September 2010 and February 2014, fifty-six
patients (29 in the EOX arm and 27 in the mDCF arm)
were randomly assigned and received at least one cycle of
the treatment (Fig. 1). Both treatment groups were well
balanced for baseline characteristics (Table 1), except for
malnutrition as assessed by initial body mass index (BMI)
(mild malnutrition according to BMI 3.5 % in EOX arm vs.
18.5 % in mDCF arm; p = 0.064) and lymphocytes level
at study entry \1500/lL (31.0 vs. 48.1 % in EOX and
mDCF arm, respectively; p = 0.300); however, these dif-
ferences were not statistically significant. Most patients had
metastatic disease and more than 50 % of patients in each
arm have undergone gastrectomy (primary tumor resec-
tion) as part of curative or palliative treatment. Signifi-
cantly more patients in the mDCF arm presented with
metastases in the liver (48.1 vs. 17.2 %; p = 0.029).
Chemotherapy
The mean duration of the first-line chemotherapy (EOX or
mDCF) did not differ between the groups (5.42 months for
EOX vs. 4.56 months for mDCF; p = 0.237). Dose
reductions due to toxicity occurred in ten patients (34.5 %)
with EOX and only one patient (3.7 %) with mDCF
(p = 0.010). Treatment delays were also more frequent in
the EOX arm (82.8 vs. 63.0 %; p = 0.171), but this dif-
ference did not reach statistical significance. The most
common adverse events leading to dose reductions and
treatment delays were neutropenia, thrombocytopenia and
fatigue. The second-line treatment with irinotecan
monotherapy was administered to 15 patients (51.7 %) in
the EOX arm compared to 11 patients (40.7 %) in the
mDCF arm (p = 0.436). Two patients (one patient in each
arm) received third-line palliative chemotherapy (Table 2).
Efficacy
Primary endpoint—overall survival
During the follow-up (median follow-up of 34 months), 27
(93.1 %) patients on EOX and 23 patients (85.2 %) on
mDCF had died. The median overall survival was
11.9 months in the mDCF compared to 9.5 months in the
EOX arm (log-rank p = 0.135) (Fig. 2). The percentage of
patients alive at 1 year was 44.4 % for mDCF and 31.0 %
for EOX and at 2 years was 22.2 % for mDCF and 5.2 %
for EOX (Table 2).
Secondary endpoint—progression-free survival
Progression-free survival did not differ significantly
between study arms. The median progression-free survival
was 6.8 months for mDCF and 6.4 months for EOX (log-
rank p = 0.440).
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Safety
The safety analysis comprises all 29 patients from the EOX
arm and 26 patients from the mDCF arm (Table 3). One
patient from the mDCF arm experienced a rapid progres-
sion of the disease after having received the first cycle of
chemotherapy. This patient did not appear in the depart-
ment again and died soon, and the data on the toxicity of
the administered first cycle of chemotherapy are unknown.
Therefore, this patient is not included in the safety analysis.
There were no statistically significant differences
between arms in toxicities of any grade or grade 3 or 4
(toxicity grade 3 or 4: EOX 79.3 % vs. mDCF 61.5 %,
p = 0.234). However, neutropenia grade 3 or 4 was
observed more frequently in the EOX arm (72.4 vs. 50.0 %;
p = 0.153). Nausea of any grade was also observed more
frequently in the EOX arm (34.5 vs. 15.4 %; p = 0.189).
The rate of thromboembolic events was twice lower in the
mDCF arm (7.7 vs. 13.8 %; p = 0.672). Interestingly,
peripheral neuropathy was observed more frequently in the
mDCF arm (15.4 vs. 6.9 %; p = 0.406).
The administration of supportive treatment during
chemotherapy was similar in both arms, except for the
granulocyte colony-stimulating factors (G-CSFs) which
were used significantly more frequently in the mDCF arm
(55.6 vs. 6.9 %; p\ 0.001) (Table 4).
Assessed for eligibility (n=60)
Not meeting inclusion criteria (n=4)
Primary analysis end point:
Overall survival (n=29)
Secondary analysis end point:
Progression free survival (n=29)
Safety (n=29)
Lost to follow-up (n=0)
Allocated to EOX (n=29)
Received EOX (n=29)
Lost to follow-up (n= 0)
Allocated to mDCF (n=27)
Received mDCF (n=27)
Primary analysis end point:
Overall survival (n=27)
Secondary analysis end point:
Progression free survival (n=27)
Safety (n=26)
Randomized (n=56)
Fig. 1 CONSORT diagram depicting the trajectory of the trial
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Discussion
This randomized trial comparing two three-drug combi-
nation palliative chemotherapy regimens in advanced
gastric and gastroesophageal junction HER2-negative
adenocarcinoma showed that mDCF chemotherapy com-
pared to EOX is associated with a 2.4-month longer overall
survival with no increase in toxicity. However, this dif-
ference is not statistically significant.
The efficacy of the EOX regimen was first established in
a randomized phase 3 trial REAL-2 [6], which evaluated
substitution of 5-fluorouracil with capecitabine and cis-
platin with oxaliplatin. The EOX regimen was associated
with a statistically significant improvement in median
overall survival compared to the original ECF regimen
(11.2 vs. 9.9 months, p = 0.02) with no increase in toxi-
city. Therefore, the EOX has become a standard palliative
chemotherapy regimen in many cancer centers. The V325
study [7] showed that the DCF combination (doc-
etaxel/cisplatin/5-fluorouracil) is more effective than CF
(cisplatin/5-fluorouracil) in terms of overall survival (9.2
vs. 8.6 months; log-rank p = 0.02), but it is associated
with increased toxicity. Therefore, modifications of the
DCF regimen were investigated with the aim of improving
its tolerability. The mDCF regimen presented by Shah at al.
[8] was shown to be at least as effective as and less toxic
Table 1 Patient demographics
and clinical characteristics
EOX N = 29 mDCF N = 27 p value
Mean age (years), (SD) 57.9 (10.8) 60.3 (9.11) 0.365
Men 16 (55.2 %) 13 (48.1 %) 0.796
ECOG performance status 1.000
0–1 26 (89.7 %) 25 (92.6 %)
2 3 (10.3 %) 2 (7.4 %)
Mean BMI at study entry, (SD) 23.5 (3.80) 23.6 (4.64) 0.893
BMI groups at study entry 0.064
17–18.99 (mild malnutrition) 1 (3.5 %) 5 (18.5 %)
19–24.99 (normal) 20 (69.0 %) 11 (40.7 %)
C25.0 (overweight) 8 (27.6 %) 11 (40.7 %)
Lymphocytes at study entry 0.300
\1500 (malnutrition) 9 (31.0 %) 13 (48.1 %)
C1500 (normal) 20 (69.0 %) 14 (51.9 %)
Previous curative treatment of gastric/GEJ adenocarcinoma 2 (6.9 %) 1 (3.7 %) 1.000
Gastrectomy 16 (55.2 %) 14 (51.9 %) 0.898
Extent of disease at study entry 0.343
Locally advanced 1 (3.4 %) 3 (11.1 %)
Metastatic 28 (96.6 %) 24 (88.9 %)
Location of metastases
Distant lymph nodes 13 (44.8 %) 13 (48.1 %) 1.000
Liver 5 (17.2 %) 13 (48.1 %) 0.029
Lungs 1 (3.4 %) 2 (7.4 %) 0.605
Peritoneum 16 (55.2 %) 12 (44.4 %) 0.593
Ovaries 2 (6.9 %) 2 (7.4 %) 1.000
Pleura 2 (6.9 %) 1 (3.7 %) 1.000
Other 3 (10.3 %) 1 (3.7 %) 0.612
Number of metastatic sites involved 0.688
0 or 1 16 (55.2 %) 13 (48.1 %)
2 11 (37.9 %) 10 (37.0 %)
C3 2 (6.9 %) 4 (14.8 %)
Lauren classification 0.765
Intestinal 5 (17.2 %) 6 (22.2 %)
Diffuse 10 (34.5 %) 10 (37.0 %)
Mixed 5 (17.2 %) 6 (22.2 %)
Unknown 9 (31.0 %) 5 (18.5 %)
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than the original DCF; the median overall survival of
15.1 months reached by patients treated with this combi-
nation was impressive. To our best knowledge, our study is
the first head-to-head randomized comparison of the EOX
and mDCF chemotherapy regimens.
The groups, although small, were well balanced in terms
of the initial characteristics, except for more frequent
malnutrition observed in the mDCF arm (18.5 vs. 3.5 %;
p = 0.064) and more frequent liver metastases in this
group of patients (48.1 vs. 17.2 %; p = 0.029). Andreyev
et al. [9] showed that in gastric and gastroesophageal
cancer patients, weight loss before the beginning of
chemotherapy is an important prognostic factor and worse
outcomes of these patients are attributable to higher toxi-
city of chemotherapy and consequently lower dose inten-
sity. It has also been shown that the presence of liver
metastases is associated with a worse overall survival [10,
11]. In this study, however, both malnutrition and liver
metastases were observed more frequently in the mDCF
arm, but still these patients had longer overall survival,
which may suggest higher efficacy of this regimen.
Dose intensity in the EOX arm was lower compared to
the mDCF arm. The mode of continuous capecitabine
administration in the EOX regimen makes use of granu-
locyte colony-stimulating factors difficult in the case of
hematological toxicity, especially neutropenia, which was
the main reason for dose delays and/or dose reductions in
the study. Indeed, dose reductions were more frequent in
the EOX arm (34.5 vs. 3.7 %; p = 0.01) as well as dose
delays (82.8 vs. 63.0 %; p = 0.171), but the second dif-
ference was not statistically significant. Significantly more
patients in the mDFC arm were administered granulocyte
colony-stimulating factors (55.6 vs. 6.9 %; p\ 0.001),
which allowed to maintain higher dose intensity in this
group.
It is also possible that adherence to treatment in the
EOX arm was lower. In theory, more frequent nausea
observed in the EOX regimen (34.5 vs. 15.4 %; p = 0.189)
might have negatively influenced the oral ambulatory
administration of capecitabine. A reduced compliance with
regard to the ambulatory administration of oral antineo-
plastic drugs is a well-known phenomenon. Although
cancer patients prefer oral medications over intravenous
therapy, about 20–30 % of them do not take pills regularly
as recommended by their treating physician. Adverse
effects of chemotherapy are among the main causes of
Table 2 Analysis of efficacy
EOX mDCF p value
Median overall survival, months (95 % CI) 9.5 (8.3–13.6) 11.9 (10.4–14.8) 0.135a
1-year survival rate, % (95 % CI) 31.0 (18.0–53.4) 44.4 (29.2–67.8)
2-year survival rate, % (95 % CI) 5.2 (0.8–32.6) 22.2 (11.0–45.0)
Median progression-free survival, months (95 % CI) 6.4 (5.3–9.0) 6.8 (3.3–9.5) 0.440a
Mean duration of first-line chemotherapy, months (SD) 5.42 (1.85) 4.56 (3.28) 0.237
At least one dose reduction 10 (34.5 %) 1 (3.7 %) 0.010
At least one cycle delay 24 (82.8 %) 17 (63.0 %) 0.171
Second-line treatment with irinotecan 15 (51.7 %) 11 (40.7 %) 0.436
Third-line treatment 1 (3.4 %) 1 (3.7 %)
a log-rank test
Fig. 2 Kaplan–Meier estimates of a overall and b progression-free
survival
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reduced adherence to oral anticancer medications. It has
been shown that adherence to oral medications correlates
with treatment efficacy [12].
It has also been reported that first-line chemotherapy
regimens containing docetaxel improve survival over
chemotherapy combinations without a taxane. A meta-
analysis of twelve randomized controlled trials including
1089 patients with palliatively resected, unresectable,
recurrent or metastatic gastric carcinoma comparing first-
line DCF chemotherapy with non-taxane-containing pal-
liative regimens showed that DCF increases response rates
and prolongs survival of patients with some increase in
toxicity [13]. Therefore, the selection of a well-tolerated
taxane-containing regimen in the first-line setting can
potentially improve the outcomes.
There were no statistically significant differences in
toxicity between the study arms; however, this lack of
significance may result from the small number of patients.
Nevertheless, grade 3 or 4 neutropenia was observed more
frequently in the EOX arm (72.4 vs. 50.0 %; p = 0.153).
The same refers to the rate of thromboembolic events
which occurred two times more often in the EOX arm (13.8
vs. 7.7 %; p = 0.672). It has been proven that throm-
boembolic events are a negative prognostic factor short-
ening the survival of cancer patients [14, 15].
Our study has several limitations. First of all, this was
a single-center study restricted to patients treated only in
our department. Secondly, because of the limited access
to CT, control imaging studies were performed every
8–12 weeks, in accordance with our routine clinical
strategy. Therefore, there may be bias in the PFS
assessment. And finally, the study was closed prematurely
due to poor patients’ accrual and resulted in small sample
size. It is therefore possible that if a small but true benefit
existed in either group, this study may have been under-
powered to detect it.
In conclusion, there is currently no one universal pal-
liative chemotherapy regimen for the treatment of
advanced gastric and gastroesophageal HER2-negative
carcinoma. Our study did not show a statistically signifi-
cant difference in median OS between compared arms.
However, we believe that a 2.4-month longer median OS
observed in the mDCF regimen is clinically important.
Although mOS of our patients treated with the mDCF
regimen was shorter than that reported by Shah et al. [8], it
is still one of the longest observed in advanced gastric
cancer. It is noteworthy that this gain in survival was
reached without an increase in toxicity of the mDCF
chemotherapy. Further randomized, large-scale trials are
necessary to confirm our results.
Table 3 Most common
treatment-related adverse events
(safety population)
EOX N = 29 mDCF N = 26
All grades Grade 3 or 4 All grades Grade 3 or 4
Anemia 13 (44.8 %) 2 (6.9 %) 16 (61.5 %) 2 (7.7 %)
Leukopenia 21 (72.4 %) 2 (6.9 %) 20 (76.9 %) 3 (11.5 %)
Neutropenia 25 (86.2 %) 21 (72.4 %) 22 (84.6 %) 13 (50.0 %)
Thrombocytopenia 6 (20.7 %) 0 (0.0 %) 5 (19.2 %) 0 (0.0 %)
Febrile neutropenia 0 (0.0 %) 0 (0.0 %) 1 (3.8 %) 1 (3.8 %)
Nausea 10 (34.5 %) 1 (3.5 %) 4 (15.4 %) 0 (0.0 %)
Vomiting 4 (13.8 %) 0(0.0 %) 3 (11.5 %) 0(0.0 %)
Diarrhea 5 (17.2 %) 1 (3.4 %) 5 (19.2 %) 1 (3.8 %)
Anorexia 8 (27.6 %) 2 (6.9 %) 7 (26.9 %) 2 (7.7 %)
Abdominal pain 4 (13.8 %) 0 (0.0 %) 2 (7.7 %) 0 (0.0 %)
Mucositis 2 (6.9 %) 0 (0.0 %) 4 (15.4 %) 0 (0.0 %)
Fatigue 9 (31.0 %) 2 (6.9 %) 6 (23.1 %) 1 (3.8 %)
Hand–foot syndrome 2 (6.9 %) 0 (0.0 %) 1 (3.8 %) 0 (0.0 %)
Thromboembolic events 4 (13.8 %) 1(3.4 %) 2 (7.7 %) 0 (0.0 %)
Peripheral neuropathy 2 (6.9 %) 0 (0.0 %) 4 (15.4 %) 0 (0.0 %)
Table 4 Supportive treatment
during chemotherapy
EOX mDCF p value
G-CSFs 2 (6.9 %) 15 (55.6 %) \0.001
Erythropoiesis-stimulating agents 3 (10.3 %) 4 (14.8 %) 0.700
Blood transfusion 3 (10.3 %) 3 (11.1 %) 1.000
Megestrol acetate 8 (27.6 %) 7 (25.9 %) 1.000
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